Oncotarget

Research Papers:

FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis

Lu Liu, Qiaoming Zhi, Meng Shen, Fei-Ran Gong, Binhua P. Zhou, Lian Lian, Bairong Shen, Kai Chen, Weiming Duan, Meng-Yao Wu, Min Tao and Wei Li _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:47145-47162. https://doi.org/10.18632/oncotarget.9975

Metrics: PDF 2350 views  |   HTML 2661 views  |   ?  


Abstract

Lu Liu1,*, Qiaoming Zhi2,*, Meng Shen1,*, Fei-Ran Gong3, Binhua P. Zhou4,5, Lian Lian1,6,7, Bairong Shen8, Kai Chen1, Weiming Duan1, Meng-Yao Wu1, Min Tao1,9,10,11, Wei Li1,4,8,9,10

1Department of Oncology, the First Affiliated Hospital of Soochow University, Suzhou, China

2Department of General Surgery, the First Affiliated Hospital of Soochow University, Suzhou, China

3Department of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China

4Markey Cancer Center, University of Kentucky, Lexington, KY, USA

5Departments of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, KY, USA

6Department of Oncology, Suzhou Xiangcheng People’s Hospital, Suzhou, China

7Department of Pathology, Suzhou Xiangcheng People’s Hospital, Suzhou, China

8Center for Systems Biology, Soochow University, Suzhou, China

9PREMED Key Laboratory for Precision Medicine, Soochow University, Suzhou, China

10Jiangsu Institute of Clinical Immunology, Suzhou, China

11Institute of Medical Biotechnology, Soochow University, Suzhou, China

*These authors contributed equally to this work

Correspondence to:

Wei Li, email: [email protected], [email protected]

Min Tao, email: [email protected], [email protected]

Meng-Yao Wu, email: [email protected]

Keywords: pancreatic cancer, FH535, β-catenin, cancer stem cell, angiogenesis

Received: February 25, 2016     Accepted: May 17, 2016     Published: June 13, 2016

ABSTRACT

The WNT/β-catenin pathway plays an important role in pancreatic cancer carcinogenesis. We evaluated the correlation between aberrant β-catenin pathway activation and the prognosis pancreatic cancer, and the potential of applying the β-catenin pathway inhibitor FH535 to pancreatic cancer treatment. Meta-analysis and immunohistochemistry showed that abnormal β-catenin pathway activation was associated with unfavorable outcome. FH535 repressed pancreatic cancer xenograft growth in vivo. Gene Ontology (GO) analysis of microarray data indicated that target genes responding to FH535 participated in stemness maintenance. Real-time PCR and flow cytometry confirmed that FH535 downregulated CD24 and CD44, pancreatic cancer stem cell (CSC) markers, suggesting FH535 impairs pancreatic CSC stemness. GO analysis of β-catenin chromatin immunoprecipitation sequencing data identified angiogenesis-related gene regulation. Immunohistochemistry showed that higher microvessel density correlated with elevated nuclear β-catenin expression and unfavorable outcome. FH535 repressed the secretion of the proangiogenic cytokines vascular endothelial growth factor (VEGF), interleukin (IL)-6, IL-8, and tumor necrosis factor-α, and also inhibited angiogenesis in vitro and in vivo. Protein and mRNA microarrays revealed that FH535 downregulated the proangiogenic genes ANGPT2, VEGFR3, IFN-γ, PLAUR, THPO, TIMP1, and VEGF. FH535 not only represses pancreatic CSC stemness in vitro, but also remodels the tumor microenvironment by repressing angiogenesis, warranting further clinical investigation.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9975